Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment

Xiao-xia Fu; Wen-jian Xiao; Jian Lu; Le-wen Wu; Fan Yang

doi:10.1007/s11655-009-0462-8

Your Location：

Home >

Browse articles >

Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment

Updated：2021-08-27

- Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment
- Chinese Journal of Integrative Medicine Vol. 15, Issue 6, Pages: 462-465(2009)
- Affiliations：
  
  1. The First Traditional Chinese Medicine Hospital of Zhanjiang City,Guangdong,China
  2. Guangdong Medical College,Guangdong,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-009-0462-8
  CLC：
- Published：2009，
  
  Published Online：18 January 2010，
Scan for full text
Fu, Xx., Xiao, Wj., Lu, J. et al. Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment., Chin. J. Integr. Med. 15, 462–465 (2009). https://doi.org/10.1007/s11655-009-0462-8

Xiao-xia Fu, Wen-jian Xiao, Jian Lu, et al. Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment. [J]. Chinese Journal of Integrative Medicine 15(6):462-465(2009)
Fu, Xx., Xiao, Wj., Lu, J. et al. Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment., Chin. J. Integr. Med. 15, 462–465 (2009). https://doi.org/10.1007/s11655-009-0462-8 DOI：

Xiao-xia Fu, Wen-jian Xiao, Jian Lu, et al. Retrospective analysis of thrombolysis therapy for 64 cases of acute myocardial infarction with elevated ST segment. [J]. Chinese Journal of Integrative Medicine 15(6):462-465(2009) DOI： 10.1007/s11655-009-0462-8.

摘要

To explore the cardiac protective effect of integrative therapy in acute myocardial infarction (AMI) with elevated ST segment after reperfusion. Sixty-four AMI patients who having received decimalization by thrombolysis were assigned to two groups by retrospective analysis

36 patients in the treated group and 28 in the control group. Both were treated by intravenous administering of urokinase for thrombolysis

and to the treated group

intravenous dripping of Xueshuantong Injection (血栓通注射液

XST) was added. Serum levels of myocardial associated enzymes were monitored before treatment and at various time points after thrombolysis

and the heart function parameters were detected with color echocardiography before treatment and on the 7th and 14th day of treatment. The patients were followed up for 6 months to observe the incidence of cardiac events. The differences between groups at the peak and peak appearing time of creatine kinase and creatine kinase isoenzyme were not significant. All the heart function parameters on the 7th and 14th day in the treated group were improved and superior to those at the corresponding time points in the control group (P<0.05

P<0.01). Incidence of some heart events in the treated group within the 6-month follow-up period was lesser than that in the control group (P<0.05). XST Injection could provide effective protection for the heart after reperfusion.

Abstract

36 patients in the treated group and 28 in the control group. Both were treated by intravenous administering of urokinase for thrombolysis

and to the treated group

intravenous dripping of Xueshuantong Injection (血栓通注射液

XST) was added. Serum levels of myocardial associated enzymes were monitored before treatment and at various time points after thrombolysis

关键词

acute myocardial infarction with elevated ST-segmentintegrative medical therapyXueshuantong Injection

Keywords

acute myocardial infarction with elevated ST-segmentintegrative medical therapyXueshuantong Injection

references

Ye RG, Lu ZY, edis. Internal medicine. 6th ed. Beijing: People’s Medical Publishing House; 2006:283–297.

Editorial board of Chinese Journal of Cardiology. Reference scheme of thrombolytic therapy of acute myocardial infarction. Chin J Cardiol (Chin) 1996;24:318–329.

He J. Research progress in pharmacological action of panax notoginseng. Tianjin Pharm (Chin) 2004;16:58–59.

Guo XH, Gao WY, Jia W, Duan HQ, Xiao PG. Research progress in pharmacological action and clinical application of chemical constituents of panax notoginseng. Chin Pract Med J (Chin) 2004;15:12.

Tang XD, Jiang JQ, Lin CW, Liu BY, Jiang DC, Gu DY. Experimental study on effects of total saponins of Panax Notoginseng on activation of NF-κb and infiltration of PMN in myocardial ischemic-reperfusion injury. J Chengdu Univ Tradit Chin Med (Chin) 2002;25:36.

Cui JT. Prevention and treatment of Panax Notoginseny on cariovascular diseases. Chin J Hosp Pharm (Chin) 1999;19:37.

Li XC. Research progress in Chinese herbs on antimyocardiali schemia injury. Chin J Modern Appl Pharm (Chin) 1998;15:1–4

Liu XP. Clinical observation on effects of panax notoginsenosidum on angina pectoris. J Emerg Tradit Chin Med (Chin) 2000;9:147.

Yu JZ, Guo DA. The proper timing of sero-enzyme examination in the thrombolytic therapy of AMI. Hainan Med J (Chin) 2004;15:9–10.

Cui JF, Pan BS. Serum enzymes markers evolution of acute myocardial infarction. Shanghai J Med Lab Sci (Chin) 2005;15:48–52.

Newby LK, Goldmann BU, Ohman EM. Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2003;41(4Suppl):31S–36S.

Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL. Cardiotrophin-I predicts death or heart failure following acute myocardial infarction. J Card Fail 2006;12:635–640.

Zhang JN, Yang GP, Su EB, Xu JD, Bian ZP, Ma WZ, et al. Study on the diagnostic of serum cardiac troponin I in acute myocardial infarction. Chin J Cardiol (Chin) 1997; 25:379–382.

Hedstrom E, Astrom-Olsson K, Ohlin H, Frogner F, Carlsson M, Billgren T, et al. Peak CK-Mb and cTnT accurately estimates myocardial infarct size after reperfusion. Scand Cardiovasc 2007;41:44–50.

Gao RL. Present situation and progress in the research into drug eluting stents. Chin J Pract Intern Med (Chin) 2006;26:1211.

FULL TEXT LINK

More>

Views

349

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰